SAN DIEGO - September 11, 2012 (Investorideas.com newswire) - Biodfense stock news; Aethlon Medical, Inc. (
OTCBB: AEMD),
disclosed this afternoon that its Chairman and CEO, Jim Joyce, and
Chief Science Officer, Dr. Richard Tullis, gave a presentation yesterday
at the MD Anderson Cancer Center in Houston, Texas. The presentation
was entitled: The extracorporeal removal of tumor-secreted exosomes: An
adjunct strategy to reverse immune suppression and inhibit metastases in
melanoma.
The presentation focused on the potential of the Aethlon
Hemopurifier® to be combined with chemo and immunotherapies as a
strategy to improve melanoma treatment outcomes. The Hemopurifier®,
which is a first-in-class device being advanced in Hepatitis C (HCV)
care, has also demonstrated the ability to capture cancer-promoting
exosomes secreted by tumors. Tumor-secreted exosomes have emerged to
become a potentially vital therapeutic target in cancer as researchers
have reported these microvesicular particles promote tumor progression
by inducing programmed cell death of anti-cancer immune cells. As a
result of inhibiting the immune response, exosomes increase the
proliferation and spread of many forms of cancer. Researchers have also
reported that exosomes seed the spread of metastasis, promote
angiogenesis (essential for tumor survival and growth), increase tumor
aggressiveness, and contribute to anti-cancer drug resistance.
"We are truly appreciative for the invitation that allowed us to
share our vision for improving metastatic melanoma care with physicians
and researchers at MD Anderson," stated Mr. Joyce.
The slide-deck of Aethlon's presentation can be accessed on the company's website at:
http://aethlonmedical. investorroom.com/ index.php?s=19.
About MD Anderson Cancer Center
Over the past 70 years, The University of Texas MD Anderson Cancer
Center has become the world's premier center devoted exclusively to the
prevention, treatment and eradication of cancer through research. For
eight of the past 10 years, MD Anderson has ranked No. 1 in cancer care
in the "Best Hospitals" survey published by U.S. News & World
Report. In fiscal year 2011, more than 108,000 people — about one-third
of them new patients — sought the high-quality care that has made MD
Anderson so widely respected. There were nearly 10,000 registrants on
clinical trials exploring novel treatments, the largest such program in
the nation.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices
that address unmet medical needs in cancer, infectious disease, and
other life-threatening conditions. Our Aethlon ADAPT™ System is a
revenue-stage technology platform that provides the basis for a new
class of therapeutics that target the selective removal of disease
enabling particles from the entire circulatory system. The Aethlon
ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address
infectious disease and cancer; HER2osome™ to target HER2+ breast cancer,
and a medical device being developed under a contract with the Defense
Advanced Research Projects Agency (DARPA) that would reduce the
incidence of sepsis in combat-injured soldiers and civilians. For more
information, please visit
www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve
risks and uncertainties. Such forward-looking statements involve
assumptions, known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of
Aethlon Medical, Inc. to be materially different from any future
results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties
include, without limitation, the ability for the Company to derive
business partnerships or future revenue streams using the Aethlon ADAPT™
system including the ability to introduce a targeted breast cancer
therapy known as HER2osome™, there is no assurance that FDA will approve
the initiation of the company's clinical programs or provide market
clearance of the company's products, the ability to achieve the goals
set out in the DARPA contract, future human studies of the Aethlon
Hemopurifier® as an adjunct therapy to improve patient responsiveness to
established cancer therapies, the company's ability to raise capital
when needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products
either internally or through outside companies and provide its services,
the impact of government regulations, patent protection on the
Company's proprietary technology, product liability exposure,
uncertainty of market acceptance, competition, technological change, and
other risk factors. In such instances, actual results could differ
materially as a result of a variety of factors, including the risks
associated with the effect of changing economic conditions and other
risk factors detailed in the Company's Securities and Exchange
Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer:
AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to
publish news and distribute content through Investordeas.com Newswire
and its syndicated partners and blogs
About Sunshine Biopharma Inc. (OTCBB: SBFM): 
Neuralstem's patented technology enables the ability to produce
neural stem cells of the human brain and spinal cord in commercial
quantities, and the ability to control the differentiation of these
cells constitutively into mature, physiologically relevant human neurons
and glia. Neuralstem is in an FDA-approved Phase I safety clinical
trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou
Gehrig's disease, and has been awarded orphan status designation by the
FDA.
Read Investorideas.com First Q&A Interview with Mr. Camille Sebaaly, CFO